Telomeres and telomerase in cancer
Telomeres have a mixed reputation when it comes to cancer. On the one hand, the chromosome-protective functions of telomeres (capping) can be lost with the shortening of telomeres that accompanies cell division, which in turn can limit cell proliferation. When telomeres become critically short and uncapped, they lose their ability to disguise the linear ends of chromosomes from the DNA damage and checkpoint response machinery, which - depending on cell context - leads to cell-cycle arrest (senescence) or cell death (1) . Thus loss of telomere reserves may stymie a clone of incipient cancer cells before it can give rise to a significant tumor. On the other hand, rare cells that have sufficiently inactivated their checkpoint response machinery (e.g., via mutation) may continue to divide despite telomere losses. In the case of cultured human fibroblasts, inactivation of the p53 and p16/Rb pathways enables bypass of senescence (2) . Uncapped telomeres are prone to recombination, including ligation to other uncapped telomeres, yielding dicentric chromosomes that, following a tug-of-war at mitosis, generate nondisjunction events or internal chromosome breaks. Cycles of these so-called breakage-fusion-bridge events drive gene sequence and copy number changes leading to cell dysfunction and death, which, in human fibroblasts that have bypassed senescence, is called crisis. But they also provide fertile ground from which rare variants can emerge to form tumors (3). Therefore, a question of fundamental importance is whether telomere losses play net inhibitory or stimulatory roles in carcinogenesis. A correlative question of greater practical importance is whether inhibition of the telomere-lengthening enzyme telomerase is likely to benefit cancer patients.
In humans, telomerase activity is under strict control, in part via epigenetic regulation of genes encoding its components, including the TERT catalytic protein and the TERC template RNA (4). Although telomerase can be detected in the progenitor cells of highly proliferative tissues, its activity is nonetheless insufficient for preventing age-related decreases in telomere lengths. Thus, telomeres would be expected to shorten in a runaway premalignant clone of cells. Indeed, premalignant lesions are characterized by extremely short telomeres, consistent with shortening limiting further cancer progression (5, 6) . Accordingly, forced telomerase expression immortalizes human cultured primary fibroblasts, pointing to the strong proliferative barriers evoked by uncapped telomeres (7) . Similarly, mTerc -/-mice, when crossed for several generations to allow telomeres to shorten significantly (e.g., G3), generally have fewer mature tumors, particularly when the p53-dependent checkpoint is intact (8) . In contrast, genome instability driven by telomere dysfunction increases the initiation of early-stage cancer lesions. For example, later generation mTerc -/-mice carrying an Apc Min allele develop higher numbers of intestinal microadenomas than mTerc +/+ Apc Min/+ or early generation mTerc -/-Apc Min/+ controls, although ultimately, the late generation mice develop fewer macroadenomas (9) . These observations raise the following question: if telomerase were activated following telomere dysfunction, would the telomere dysfunction promote or inhibit carcinogenesis overall? The nearly ubiquitous presence in human cancers of telomere length-maintenance mechanisms (usually telomerase, or sometimes an alternative recombination-based mechanism called ALT) together with the capacity of telomerase inhibition to compromise tumor growth suggest that functional telomeres are critical to cancer progression (10) .
Novel mouse models addressing roles for telomeres and telomerase in carcinogenesis
To address the capacity of telomerase to support carcinogenesis following telomere dysfunction, in this issue of the JCI, BegusNahrmann et al. report on their creation of a mouse carrying a liver-specific doxycyclineinducible (DOX-inducible) transgene encoding a dominant-negative form of TRF2 (11) . TRF2 is a component of a protein complex called Shelterin and plays critical roles in telomere capping, in part by preventing the ATM checkpoint kinase from recognizing the telomere as broken DNA (12) . A clever feature of this system is that, since transient telomere dysfunction (TTD, i.e., uncapping) can be induced at any time in animals possessing functional telomerase, TTD effects can be addressed at different stages of cancer progression.
When the transgenic mice were treated at 15 days of age with a hepatocellular carcinoma-inducing (HCC-inducing) agent diethylnitrosamine (DEN), followed by treatment with DOX at 2 to 3 months of age to induce TTD prior to the development of tumors, the numbers of microscopic dysplastic foci and fully developed tumors appearing at 6 to 12 months of age were increased compared with those in mice in which telomere capping was maintained. TTD induction also elevated rates of chromosome aberrations, suggesting that higher rates of oncogenic mutations enhanced tumorigenesis. In contrast, DENtreated G3 mTerc -/-mutants developed less numerous and smaller tumors than even the non-DOX induced TTD strain, despite increased numbers of chromosome aberrations and dysplastic foci (Table 1) . Therefore, TTD enhances the initiation of HCC cancers, but persistent telomere dysfunction is deleterious to cancer cell survival, and thus telomerase facilitates the development into mature tumors of early lesions that have experienced telomere dysfunction. Furthermore, by inducing TTD in mice with established HCC at 11 to 13 months of age and following tumor growth using MRI, the authors observed increased tumor size in the DOX-treated mice relative to the controls, indicating that TTD can also aid in cancer progression (11) .
Curiously, telomere lengths in TTDinduced tumors were shorter than those in tumors from mice in which telomere dysfunction was not induced. The authors suggest that TTD specifically enhances tumor formation in cells with short telomeres. How this short telomere phenotype is maintained in the presence of telomerase is unclear, but it is interesting that modest telomere lengths are often found in telomerase-positive cancers and that there are correlations between chromosome aberrations and short telomeres in human tumors (13) , suggesting that short telomeres may convey some advantage to cancer cells.
Findings complementary to those of Begus-Nahrmann et al. have just been published by the DePinho group, which engineered systems for restoring telomerase activity within an mTert -/-background (14, 15) . Pten -/-p53 -/-mutant mice (naturally possessing telomerase) displayed early prostate cancer lesions by nine weeks of age and developed large and invasive adenocarcinomas by 24 weeks. Although G3/G4 mTert -/-Pten -/-p53 -/-mice also showed cancer initiation by nine weeks, few tumors progressed further, and those that did remained small and were accompanied by high levels of apoptosis and DNA damage checkpoint activation compared with telomerase-positive counterparts. Thus, although critical telomere shortening due to telomerase deficiency may aid cancer initiation, progression is hampered by subsequent apoptosis and DNA-damage responses. Importantly, telomerase-deficient G3/G4 mice in which telomerase was restored at the point of cancer initiation developed invasive carcinomas after 24 weeks, similarly to naturally telomerase-proficient mice. Moreover, 25% of these mice also displayed skeletal metastases, again suggesting that periods of TDD-induced genome instability, followed by telomerase-dependent stabilization, can promote cancer progression (14) . Similar results were obtained using mTertand Atm-deficient mice in which induction of transgenic mTert stimulated T cell lymphomas. Of note, subsequent inactivation of telomerase in the tumors selected for telomere lengthening by ALT, again point- (14) . Thus, despite differences in human and mouse telomere biology (see below), the mouse models have proven themselves valuable guides on the path to understanding human cancer.
Implications of the new findings
The new findings suggest that TTD in cells possessing active telomerase or in whose progeny telomerase can become activated can contribute to cancer progression. Telomerase inhibitors are being actively tested in clinical trials for cancer, and the new findings raise the possibility that short-term telomerase inhibition in mature tumors will do more harm than good, i.e., TTD might stimulate the appearance of new mutant clones, some of which could promote tumor progression. By the same token, the new findings are consistent with evidence that long-term inhibition of telomerase may be of therapeutic benefit. Also of note, inhibition of telomerase may favor the appearance of tumor subclones that use ALT to maintain telomeres, although as described in the next section, ALT probably emerges at lower frequencies in human than in murine premalignant cells. Thus, studies of telomerase inhibitors as potential therapies for human cancer certainly remain important avenues of investigation.
Caveats based on differences between mice and humans
It is important to note that the new findings might overestimate the importance of TDD in promoting carcinogenesis in humans because of several key differences between mouse and human telomere biology. Telomere lengths of inbred mouse lines are approximately five times those of humans. Secondly, telomerase activity is less restricted in mice (16) , and thus cells that have incurred a period of TDD are more likely to be rescued by telomerase in mice than in humans. Finally, although human and murine cells share p53-dependent checkpoint responses to telomere dysfunction, human cells possess additional responses, including a p16/INK4a-dependent checkpoint (17, 18) . This may help prevent human cells from bypassing checkpoints to adopt telomerase or ALT-based mechanisms of telomere maintenance (which occur at higher frequencies in mice). Considering these factors, it appears that humans may have evolved a system designed to use telomere shortening as a guard against cancer, whereas mice, which generally maintain telomeres in a capped state, respond less robustly when capping is lost. These considerations may in part explain the approximately 10,000-fold higher rates of cancer, corrected for cell divisions and life span, in mice compared with humans and are consistent with the dramatic capacity of forced expression of telomerase to immortalize cultured human fibroblasts at crisis (~10 7 -fold stimulation) compared with the modest effect in murine fibroblasts (~2-fold stimulation) (7). Overall, it seems likely that in human cells, the robust checkpoint responses to telomere dysfunction coupled with controls on telomerase enable telomeres to subserve an anticancer function. Nonetheless, in settings where telomeres are pathologically short, e.g., due to high mucosal cell turnover caused by immune-mediated damage in inflammatory bowel disease or due to telomerase deficiency in dyskeratosis congenita patients (8) , the protumorigenic effects of TTD may be magnified. In these conditions, perhaps the large numbers of cells with telomere dysfunction compared with the small number of premalignant cells with short telomeres in normal individuals provide greater opportunity for emergence of tumorigenic cells overall. Additional investigations, including detailed studies of telomere dynamics at different stages of carcinogenesis in human tissues, are needed to evaluate these ideas further.
Open questions
Several questions are raised by the new sets of findings: might transient inhibition of telomerase in cancer patients be potentially harmful, and will sustained inhibition be required for therapeutic benefit? How significant is the possibility that telomerase inhibition will select for ALT-dependent tumor subclones? Furthermore, at what stages of tumorigenesis does functionally important telomere uncapping occur? Assays designed to address telomere capping (rather than telomere length) will be useful in addressing this question (1, 19, 20) . Finally, do the broad age-related declines in telomere lengths in multiple tissues serve to promote carcinogenesis in the elderly? Although telomere shortening in rare cells that are dividing out of control within a young individual may serve to inhibit cancer progression, if most cells within an elderly individual naturally have shortened telomeres, the net effect may be to promote cancer. Answers to these questions will aid in tailoring telomere-related cancer therapies for young and old alike.
It is increasingly accepted that most, if not all, conventional cytotoxic cancer therapies rely upon eliciting programmed cell death (apoptosis) in the tumor cells, a process regulated principally by the BCL-2 protein family (1) . Interactions among the members of this family serve as a switch determining whether the cell will live or die. In response to intracellular damage, the distant cousins of BCL-2, called BH3-only proteins because they bear only the third of the four BCL-2 homology domains that characterize this family, are activated and convey the cell death warrant. They use their BH3 domain to engage and neutralize their prosurvival relatives, e.g., BCL-2, BCL-x L , and MCL-1, keeping these cell guardians from restraining the family's critical effector proteins, BAX and BAK. Once the guardians have been overcome, certain potent BH3-only proteins (e.g., BIM) can also directly activate BAX and BAK, which then damage the mitochondria and unleash the proteolytic cascade that culminates in cell death (1).
The prospects of BH3 mimetics
Oncologists have long dreamed of drugs that would directly flip the apoptotic switch in cancer cells. That dream inspired the development of the first BH3 mimetic drugs (reviewed in refs. 1, 2), the best studied of which are ABT-737 (3) and its orally bioavailable derivative ABT-263 (4). These drugs are specific for certain prosurvival BCL-2 family members; for example, they bind BCL-2 and BCL-x L with high affinity but not MCL-1 ( Figure 1A) . Consequently, as single agents they kill cells whose survival depends primarily on BCL-2 and/or BCL-x L but not those containing sufficient MCL-1 to restrain BAX, unless another agent inactivates or eliminates MCL-1 (5). The many promising preclinical findings with ABT-737 and ABT-263 have led to clinical trials of the latter. Notably, with chronic lymphocytic leukemia, which is sustained by high levels of BCL-2, ABT-263 has shown substantial efficacy as a single agent in one-third of patients, even in cases refractory to all conventional therapies and with poor prognostic markers (6) .
In vitro and in vivo, ABT-263 and ABT-737 can greatly augment the action of diverse conventional chemotherapeutics (3, 4) , most likely because those agents diminish active MCL-1 levels, but which drug combinations will be tolerable in the clinic remains unclear. For example, the ability of ABT-737 and ABT-263 to engage BCL-x L , which is the principal guardian of platelet survival (7), provokes a transient thrombocytopenia, and that has proven to be the dose-limiting toxicity for ABT-263 (6). Consequently, a novel BH3-mimetic highly specific for BCL-2 (ABT-199), which has recently entered clinical trial, should permit higher doses and have even greater promise for chronic lymphocytic leukemia and other diseases sustained by BCL-2 (1).
Eventually, BH3 mimetics that effectively target other family members (e.g., MCL-1) are likely to be developed, but the path to such agents is arduous, because as yet no defined organic skeleton adequately mimics the a-helix assumed by the 16- to 26-residue BH3 domain upon binding to the hydrophobic groove on the surface of its prosurvival relatives. Hence, the development of a new BH3 mimetic typically commences with screens of some 10 6 chemical building blocks for binding to the BCL-2 family protein target; the resulting weak "hits" must be modified iteratively over
